Navigation Links
Luminex Corporation to Present at JP Morgan Healthcare Conference
Date:1/4/2012

AUSTIN, Texas, Jan. 4, 2012 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the 30th Annual JP Morgan Healthcare Conference to be held January 9 -12, 2012, in San Francisco, CA.

(Logo:  http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

The investor presentation by Patrick J. Balthrop, president and chief executive officer, will begin at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) on Wednesday, January 11, 2012.  The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com.  Simply log on to the web at the address above, go to the Company section and access the Investor Relations link.  Please go to the website at least 15 minutes prior to the event to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the presentation will be archived for six months on the website using the 'replay' link.

ABOUT LUMINEX CORPORATION Luminex is committed to applying its passion for innovation toward advancing healthcare and research worldwide. The Company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP® open-architecture, multi-analyte platform and MultiCode® real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies, that deliver cost-effective and rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. The Company is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, bio-defense research and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology, please visit http://www.luminexcorp.com.Contacts:

Harriss T. Currie 

Chief Financial Officer 

Vice President Finance 

512-219-8020 

  

Matthew Scalo 

Sr. Director of Investor Relations 

512-219-8020 

mscalo@luminexcorp.com 

  


'/>"/>

SOURCE Luminex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Luminex Corporation Joins Forces With the National Marrow Donor Program - Be The Match®
2. Neogen Corporation Announces 2nd Quarter Results Conference Call
3. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
4. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
5. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
6. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
7. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
8. China Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 19, 2011
9. China Cord Blood Corporation Files Its Annual Report on Form 20-F
10. McKesson Corporation Unveils New Offerings to Empower the Community Patient Care Delivery System
11. Spectros Corporation Signs Distribution Agreements in Korea, Switzerland, Denmark
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, doctors ... being treated for breast cancer benefitted from an injection of stem cells derived from ... frequent side effect of cancer treatment. , Lymphedema refers to the swelling ...
Breaking Biology Technology:
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/9/2016)... , June 9, 2016 ... Police deploy Teleste,s video security solution to ensure the safety ... France during the major tournament Teleste, ... communications systems and services, announced today that its video security ... to back up public safety across the country. ...
(Date:6/2/2016)... , June 2, 2016 Perimeter ... Platforms, Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... market will generate revenues of $17.98 billion in 2016. ... DVTEL Inc, a leader in software and hardware technologies ...
Breaking Biology News(10 mins):